Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy

Food Allergy Peanut Clinical Trial

Official title:
Intra-lymphatic Immunotherapy for the Management of Peanut Allergy

Status Withdrawn

Clinical Trial Summary

Use of three intralymphatic injections of peanut allergen one month apart to induce tolerance to peanut in peanut allergic people.

Clinical Trial Description

Eligible subject undergo a baseline blinded oral peanut challenge. Then the peanut ILIT as described above. Pretreatment with antihistamines, leukotriene modifier and albuterol before each treatment. Following the three ILIT peanut injections a repeat blinded oral peanut challenge is performed. Blood is drawn at each of the 5 study visits for a variety of tests trying to elucidate the mechanism(s) of the induction of tolerance to peanut. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04200989
Study type	Interventional
Source	Scripps Health
Contact
Status	Withdrawn
Phase	Phase 1/Phase 2
Start date	March 1, 2021
Completion date	December 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06260956` - Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg	N/A
Enrolling by invitation	`NCT04604431` - Intervention to Reduce Early (Peanut) Allergy in Children	N/A
Not yet recruiting	`NCT05407012` - TRANS-FOODS: Preventing Peanut Allergy Through Improved Understanding of the Transcutaneous Sensitisation Route, Novel Food Processing and Skin Care Adaptations	N/A
Recruiting	`NCT06192914` - EPAP, Interviewstudy
Recruiting	`NCT05695261` - Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients	Phase 2
Completed	`NCT05038904` - Preventing Anaphylaxis With Acalabrutinib	Phase 2